How long should I take Ibrutinib?

IbrutinibIbrutinib is usually administered before disease progression or unacceptable toxicity or, in the case of graft-versus-host disease, before recurrence of the underlying malignancy. In clinical trials for CLL, the average duration of ibrutinib therapy was approximately 41 months. Ibrutinib is typically used indefinitely if it is well tolerated, has limited disease progression, and does not exhibit toxicities.

In some people, very good partial clinical responses may occur within three to six months. However, most people are kept on ibrutinib indefinitely, regardless of clinical response. This is a common treatment strategy for people with certain types of leukemia and solid tumors because often when the therapeutic agent is stopped, symptoms return within a relatively short period of time and the lymph nodes enlarge, especially if the patient has not been taking ibrutinib for a long time or if they have tried many other previous treatments. The average duration of ibrutinib therapy in clinical trials was approximately 41 months (range 2-51 months). Among patients who discontinued ibrutinib, the median survival after discontinuation was 8 months.

There are generic drugs in Bangladesh, Laos and India, with different manufacturers, different specifications, and different prices. The price per box is about 1000 to 2000. Patients can choose the drug version according to their own economic situation. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.